Drug profile · INN
dasiprotimut-t
LYMPREVA
dasiprotimut-t (LYMPREVA) is an FDA-listed pharmaceutical active ingredient.
EMA: refused Antineoplastic and immunomodulating agents (L03) L03AX
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — dasiprotimut-t
- Class
- Antineoplastic and immunomodulating agents (L03)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
dasiprotimut-t (LYMPREVA) is an FDA-listed pharmaceutical active ingredient.
Key facts
INN dasiprotimut-t
Brand LYMPREVA
Therapeutic class Antineoplastic and immunomodulating agents (L03)
ATC code L03AX
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | refused | — |
Related & competitor drugs
Frequently asked questions
What is dasiprotimut-t?
dasiprotimut-t (LYMPREVA) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for dasiprotimut-t?
LYMPREVA is a marketed brand name for dasiprotimut-t. Check FDA Drugs@FDA for the current US label holder and prescribing information.